Treprostinil

The U.S. Food and Drug Administration accepted United Therapeutics’ supplemental New Drug Application for nebulized Tyvaso (treprostinil) in idiopathic pulmonary fibrosis. The company expects the review to conclude in late April 2027. Acceptance confirms…